33621-61-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
2-AMINO-5-(4-CHLOROPHENYL)-1,3,4-OXADIA& is utilized as a key compound in pharmaceutical research and drug development due to its potential biological activity and versatile properties. It is particularly valued for its potential applications in treating a range of conditions.
Used in Anti-Cancer Applications:
In the field of oncology, 2-AMINO-5-(4-CHLOROPHENYL)-1,3,4-OXADIA& is used as an anti-cancer agent, targeting various types of cancer. Its specific mechanism of action and interaction with biological systems are under investigation to leverage its potential in combating cancer cells.
Used in Anti-Inflammatory Applications:
2-AMINO-5-(4-CHLOROPHENYL)-1,3,4-OXADIA& is also considered for its anti-inflammatory properties, making it a candidate for the development of treatments aimed at reducing inflammation and associated symptoms in various conditions.
Used in Antiviral Applications:
2-AMINO-5-(4-CHLOROPHENYL)-1 3 4-OXADIA& has shown promise in antiviral research, potentially serving as a therapeutic agent against viral infections. Its antiviral properties are being studied to understand its efficacy and mechanism of action against different viral strains.
Used in Neurological Disorder Treatment:
2-AMINO-5-(4-CHLOROPHENYL)-1,3,4-OXADIA& has demonstrated potential in the treatment of neurological disorders, offering a new avenue for research into diseases affecting the brain and nervous system. Its role in managing or treating such disorders is under active investigation.

Upstream product

• 64310-32-3 1-(4-chlorobenzoyl)thiosemicarbazide 
• 5315-86-6 4-chlorobenzaldehyde semicarbazone 
• 536-40-3 4-chlorobenzoic acid hydrazide 
• 23275-53-8 5-(4-chlorophenyl)-1,2,4-oxadiazol-3-amine 
• 4426-72-6 hydrazine carboxamide 
• 74-11-3 para-chlorobenzoic acid 
• 104-88-1 4-chlorobenzaldehyde 
• 563-41-7 semicarbazide hydrochloride 
• 122-01-0 4-chloro-benzoyl chloride 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 506-68-3 bromocyane 
• 199339-17-8 2-[(Z)-5-(4-Chloro-phenyl)-[1,3,4]oxadiazol-2-ylimino]-5-methyl-thiazolidin-4-one 
• 855737-94-9 1-(4-chloro-benzoyl)-S-methyl-iso thiosemicarbazide 
• 141-52-6 sodium ethanolate 

Downstream Products

• 67454-91-5 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-ylamino]-methanol 
• 25306-20-1 2-(4-chlorophenyl)imidazo[2,1-b][1,3,4]oxadiazol-5,6-dione 
• 13751-24-1 1-(4-Chlor-benzoyl)-5-carbamoyl-diaminoguanidin 
• 53297-65-7 2,6-bis-(4-chloro-phenyl)-[1,3,4]oxadiazolo[3,2-a][1,3,5]triazine-5,7-dione 
• 6694-45-7 1-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl)-3-phenylurea 
• 6783-24-0 1-<5-p-Chlorphenyl-1.3.4-oxdiazolyl-(2)>-phenyl-uretdion 
• 34254-11-0 3-chloroacetyl-5-(4-chloro-phenyl)-3H-[1,3,4]oxadiazol-2-ylideneamine 
• 34257-05-1 5-(4-chloro-phenyl)-3-(3-chloro-propionyl)-3H-[1,3,4]oxadiazol-2-ylideneamine 
• 37423-08-8 N'-[5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-N,N-dimethyl-formamidine 
• 53297-67-9 6-(3-chloro-phenyl)-2-(4-chloro-phenyl)-[1,3,4]oxadiazolo[3,2-a][1,3,5]triazine-5,7-dione 
• 51324-06-2 2-<4-Chlor-phenyl>-5-oxo-7-aethoxycarbonyl-1,3,4-oxadiazolo<3,2-a>pyrimidin 
• 51323-97-8 2-(4-chloro-phenyl)-[1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one 
• 72481-50-6 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-phosphorimidic acid trichloride 
• 72481-55-1 [5-(4-chloro-phenyl)-[1,3,4]oxadiazol-2-yl]-phosphoramidic acid dichloride 

Relevant academic research and scientific papers

In Silico Study and In Vitro Evaluation of Novel Synthesized Quinolone Derivatives Having Five-Membered Heterocyclic Moieties

Infectious diseases are caused by pathogens, such as viruses, bacteria, fungi, and parasites. Quinolones work by inhibition of bacterial topoisomerase IV and/or gyrase, a group of oxadiazole derivatives were incorporated into C7 piperazine ring of Gatiflo

Synthesis, telomerase inhibitory and anticancer activity of new 2-phenyl-4H-chromone derivatives containing 1,3,4-oxadiazole moiety

Based on previous studies, 66 2-phenyl-4H-chromone derivatives containing amide and 1,3,4-oxadiazole moieties were prepared as potential telomerase inhibitors. The results showed most of the title compounds exhibited significantly inhibitory activity on telomerase. Among them, some compounds demonstrated the most potent telomerase inhibitory activity (IC50 50 = 6.41 μM). In addition, clear structure–activity relationships were summarised, indicating that the substitution of the methoxy group and the position, type and number of the substituents on the phenyl ring had significant effects on telomerase activity. Among them, compound A33 showed considerable inhibition against telomerase. Flow cytometric analysis showed that compound A33 could arrest MGC-803 cell cycle at G2/M phase and induce apoptosis in a concentration-dependent way. Meanwhile, Western blotting revealed that this compound could reduce the expression of dyskerin, which is a fragment of telomerase.

Synthesis, in vitro α-glucosidase inhibitory potential and molecular docking studies of 2-amino-1,3,4-oxadiazole derivatives

Background: In the recent past, we have synthesized and reported different derivatives of oxadiazoles as potential α-glucosidase inhibitors, keeping in mind, the pharmacological aspects of oxadiazole moiety and in continuation of our ongoing research on the chemistry and bioactivity of new heterocyclic compounds. Methods: 1,3,4-Oxadiazole derivatives (1-14) have been synthesized and characterized by different spectroscopic techniques such as1 H-,13 C-NMR and HREI-MS. Results: The synthetic derivatives were screened for α-glucosidase inhibitory potential. All compounds exhibited good inhibitory activity with IC50 values ranging between 0.80 ± 0.1 to 45.1 ± 1.7 μM in comparison with the standard acarbose having IC50 value 38.45 ± 0.80 μM. Conclusion: Thirteen compounds 1-6 and 8-14 showed potential inhibitory activity as compared to the standard acarbose having IC50 value 38.45 ± 0.80 μM, however, only one compound 7 (IC50 = 45.1 ± 1.7 μM) was found to be less active. Compound 14 (IC50 = 0.80 ± 0.1 μM) showed promising inhibitory activity among all synthetic derivatives. Molecular docking studies were also conducted for the active compounds to understand the ligand-enzyme binding interactions.

Ultrapotent Inhibitor of Clostridioides difficile Growth, Which Suppresses Recurrence in Vivo

Clostridioides difficile is the leading cause of healthcare-associated infection in the U.S. and considered an urgent threat by the Centers for Disease Control and Prevention (CDC). Only two antibiotics, vancomycin and fidaxomicin, are FDA-approved for the treatment of C. difficile infection (CDI), but these therapies still suffer from high treatment failure and recurrence. Therefore, new chemical entities to treat CDI are needed. Trifluoromethylthio-containing N-(1,3,4-oxadiazol-2-yl)benzamides displayed very potent activities [sub-μg/mL minimum inhibitory concentration (MIC) values] against Gram-positive bacteria. Here, we report remarkable antibacterial activity enhancement via halogen substitutions, which afforded new anti-C. difficile agents with ultrapotent activities [MICs as low as 0.003 μg/mL (0.007 μM)] that surpassed the activity of vancomycin against C. difficile clinical isolates. The most promising compound in the series, HSGN-218, is nontoxic to mammalian colon cells and is gut-restrictive. In addition, HSGN-218 protected mice from CDI recurrence. Not only does this work provide a potential clinical lead for the development of C. difficile therapeutics but also highlights dramatic drug potency enhancement via halogen substitution.

Synthesis of indole-tethered [1,3,4]thiadiazolo and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids as anti-pancreatic cancer agents

New indole-tethered [1,3,4]thiadiazolo[3,2-a]pyrimidin-5-one (8a-j) and [1,3,4]oxadiazolo[3,2-a]pyrimidin-5-one hybrids (9a-e) were synthesized using [4+2] cycloaddition reactions of functionalized 1,3-diazabuta-1,3-dienes with indole-ketenes. All molecul

Synthesis and antitubercular activity of new N-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-(nitroheteroaryl)carboxamides

Nitro-substituted heteroaromatic carboxamides 1a-e were synthesized and tested against three Mycobacterium tuberculosis cell lines. The activities can be explained in terms of the distribution of the electronic density across the nitro-substituted heteroaromatic ring attached to the amide group. 1,3,5-Oxadiazole derivatives 1c-e are candidates for the development of novel antitubercular agents. Ongoing studies are focused on exploring the mechanism by which these compounds inhibit M. tuberculosis cell growth.

Synthesis, in vitro and in silico Anti-Proliferative Studies of Novel Piperiene-Oxadiazole and Thiadiazole Analogs

Piperine is a component of pepper which has earlier been reported as anticancer active compound. This work is emphasized on the design and synthesis of new hybrid piperine analogs by coupling piperine with the amine group of oxadiazoles and thiadiazoles.

Synthesis and amelioration of inflammatory paw edema by novel benzophenone appended oxadiazole derivatives by exhibiting cyclooxygenase-2 antagonist activity

Ten new 2(4-hydroxy-3-benzoyl) benzamide-5-phenyl-1,3,4-oxadiazole derivatives (10a–j) were synthesized by coupling 3-benzoyl-4-hydroxybenzoic acid (5) with 2-amino-5-phenyl-1,3,4-oxadiazoles (9a–j). The structures of these compounds were confirmed by IR, 1H, 13C NMR, and mass spectra, and also by elemental analyses. The anti-inflammatory activity of the compounds 10a–j were investigated by screening them against human red blood cells (HRBC) in-vitro. The results reveal that among this series, compound 10j with hydroxy substituent, particularly at the ortho position of the phenyl ring attached to the 5th carbon atom of the oxadiazole ring possess significant membrane stabilizing activity in comparison with the control. Further, in-vivo chick chorioallantoic membrane (CAM) and rat corneal anti-angiogenesis assays were performed to assess the effect of compound 10j on endothelial cell migration. This confirmed that compound 10j inhibits the proliferation of endothelial cells. Anti-inflammatory studies detected the amelioration of carrageen induced rat hind paw edema. Further in-vivo and in-silico approaches revealed the inhibition of inflammatory marker enzyme cyclooxygenase-2 (Cox-2) and myleoperoxidase (MPO). The study reports that the compound 10j effectively act against the inflammatory mediated anti-angiogenic disorders which could be translated into a new drug in future.

Spiro-heterocycles containing 1,3,4-oxadiazole: A convenient synthesis of 3-(5- Substitutedphenyl-l,3,4-oxadiazole-2-yl)-5,8-dithiaspiro[3,4]-octan-2-onesand 1,4-dithia-6-azaspiro[4,4]-nonan-7-ones

A new series of novel 3-(5-substituted phenyl-l,3,4-oxadiazole-2-yl)-5,8-dithiaspiro [3,4]-octan-2-ones and l,4-dithia-6- azaspiro[4,4]nonan-7-ones have been synthesized from a common intermediate, in good yields. These compounds have been screened for th

Ultrasound-assisted synthesis of 2-amino-1,3,4-oxadiazoles through NBS-mediated oxidative cyclization of semicarbazones

A ultrasound-assisted oxidative cyclization of semicarbazones using N-bromosuccinimide in the presence of sodium acetate was established providing efficient and rapid access to a variety of 2-amino-1,3,4-oxadiazoles. Moreover, the new synthetic protocol provides a simple procedure utilizing a safer oxidizing system that affords the target products in high regioselectivity, satisfactory yields, and elevated purities.